Royalty Pharma (NASDAQ:RPRX) Upgraded at StockNews.com

Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

Several other brokerages have also weighed in on RPRX. Citigroup cut their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, October 25th. The Goldman Sachs Group lifted their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, Morgan Stanley upped their price objective on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.67.

Royalty Pharma Trading Down 3.3 %

Shares of Royalty Pharma stock opened at $26.64 on Tuesday. Royalty Pharma has a fifty-two week low of $25.20 and a fifty-two week high of $31.66. The business’s fifty day moving average is $27.93 and its two-hundred day moving average is $27.56. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The firm has a market cap of $15.81 billion, a PE ratio of 23.58, a P/E/G ratio of 4.00 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.01. The firm had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period in the prior year, the business posted $0.85 earnings per share. Analysts anticipate that Royalty Pharma will post 4.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in RPRX. Xponance Inc. raised its holdings in shares of Royalty Pharma by 1.9% during the 2nd quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company’s stock valued at $836,000 after buying an additional 606 shares during the period. EverSource Wealth Advisors LLC grew its position in Royalty Pharma by 32.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 655 shares in the last quarter. Values First Advisors Inc. raised its stake in shares of Royalty Pharma by 7.6% during the third quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 738 shares during the period. Phillips Wealth Planners LLC lifted its position in shares of Royalty Pharma by 10.2% during the third quarter. Phillips Wealth Planners LLC now owns 8,733 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 808 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Royalty Pharma by 10.8% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company’s stock valued at $276,000 after purchasing an additional 887 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.